MXPA01006006A - Cadena receptora de citocina. - Google Patents

Cadena receptora de citocina.

Info

Publication number
MXPA01006006A
MXPA01006006A MXPA01006006A MXPA01006006A MXPA01006006A MX PA01006006 A MXPA01006006 A MX PA01006006A MX PA01006006 A MXPA01006006 A MX PA01006006A MX PA01006006 A MXPA01006006 A MX PA01006006A MX PA01006006 A MXPA01006006 A MX PA01006006A
Authority
MX
Mexico
Prior art keywords
cytokine receptor
receptor chain
methods
receptor
disclosed
Prior art date
Application number
MXPA01006006A
Other languages
English (en)
Spanish (es)
Inventor
Tamlyn Neben
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22786499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA01006006(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of MXPA01006006A publication Critical patent/MXPA01006006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA01006006A 1998-12-14 1999-12-13 Cadena receptora de citocina. MXPA01006006A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21133598A 1998-12-14 1998-12-14
PCT/US1999/029493 WO2000036103A1 (en) 1998-12-14 1999-12-13 Cytokine receptor chain

Publications (1)

Publication Number Publication Date
MXPA01006006A true MXPA01006006A (es) 2004-08-12

Family

ID=22786499

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01006006A MXPA01006006A (es) 1998-12-14 1999-12-13 Cadena receptora de citocina.

Country Status (16)

Country Link
US (1) US7507706B1 (enExample)
EP (1) EP1141286B1 (enExample)
JP (3) JP5519087B2 (enExample)
CN (2) CN1352686A (enExample)
AT (1) ATE342976T1 (enExample)
AU (1) AU780031B2 (enExample)
BR (1) BR9916209A (enExample)
CA (1) CA2356779C (enExample)
CY (1) CY1107657T1 (enExample)
DE (1) DE69933696T2 (enExample)
DK (1) DK1141286T3 (enExample)
ES (1) ES2277460T3 (enExample)
MX (1) MXPA01006006A (enExample)
NZ (1) NZ512942A (enExample)
PT (1) PT1141286E (enExample)
WO (1) WO2000036103A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
EP2027867A1 (en) * 2000-10-20 2009-02-25 Genetics Institute, LLC Method and composition for inhibition of tumor growth and enhancing an immune response
EP1587534A1 (en) * 2003-01-17 2005-10-26 Children's Hospital Medical Center Use of tff2, or agents inducing tff2, in the therapy of allergies
CA2512808A1 (en) * 2003-01-18 2004-08-12 Marc Elliot Rothenberg Regulation of allergen induced gene
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
WO2004092404A2 (en) * 2003-04-11 2004-10-28 Wyeth Inhibitors of acidic mammalian chitinase as asthma therapeutics
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
PL1711528T3 (pl) 2003-12-23 2012-11-30 Genentech Inc Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
US20070178520A1 (en) * 2004-02-27 2007-08-02 Barbara Wolff-Winiski Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
MX2007005866A (es) 2004-11-17 2007-11-12 Amgen Inc Anticuerpos monoclonales totalmente humanos para il-13.
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
RU2009140134A (ru) * 2007-04-23 2011-05-27 Вайет (Us) Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
EP2162743A4 (en) * 2007-05-29 2010-07-14 Univ Cincinnati METHOD FOR MODULATING IGNITION AND COMPOSITIONS THEREFOR
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
CN105722532A (zh) 2013-09-13 2016-06-29 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
CA3059731A1 (en) 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5011778A (en) 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
CZ283050B6 (cs) 1989-12-20 1997-12-17 Schering Corporation Polypeptid, jeho subsekvence a jejich použití
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5246701A (en) 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
ATE130869T1 (de) 1991-03-29 1995-12-15 Sanofi Sa Protein mit der aktivität vom typ von cytokin, dafür kodierende rekombinante dns, transformierte zellen und mikroorganismen.
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
WO1994004680A1 (en) 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
EP0721346B1 (en) 1993-09-02 1998-06-10 Trustees of Dartmouth College Methods for inducing antigen-specific t cell tolerance
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
EP0907730B1 (en) * 1995-10-23 2009-10-07 Zenyth Operations Pty Ltd Haemopoietin receptor and genetic sequences encoding same
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
WO1997033913A1 (en) * 1996-03-13 1997-09-18 Zymogenetics, Inc. Cytokine-receptor expressed in testis cells
EP0812913A3 (en) * 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
AU6175696A (en) * 1996-06-12 1998-01-07 Human Genome Sciences, Inc. Hr-1 receptor
WO1997047742A1 (en) * 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
TR200001247T2 (tr) 1997-01-10 2002-06-21 Biogen Inc. Anti-CD40L bileşikleri ile lupus nefritis tedavisi.
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
GB9723553D0 (en) 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
AU5756100A (en) 1999-06-21 2001-01-09 Genetics Institute Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
AU2000278349A1 (en) 1999-09-28 2001-04-30 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin 13 gene
EP1222212A4 (en) 1999-10-06 2005-05-04 Penn State Res Found MUTANTS OF IL-13
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof

Also Published As

Publication number Publication date
ATE342976T1 (de) 2006-11-15
CN1352686A (zh) 2002-06-05
PT1141286E (pt) 2007-01-31
US7507706B1 (en) 2009-03-24
CN104611339A (zh) 2015-05-13
DK1141286T3 (da) 2007-02-19
EP1141286A1 (en) 2001-10-10
EP1141286B1 (en) 2006-10-18
CA2356779A1 (en) 2000-06-22
AU2177500A (en) 2000-07-03
DE69933696T2 (de) 2007-08-23
CA2356779C (en) 2012-03-13
JP2014113165A (ja) 2014-06-26
AU780031B2 (en) 2005-02-24
DE69933696D1 (de) 2006-11-30
WO2000036103A1 (en) 2000-06-22
WO2000036103A9 (en) 2002-04-11
JP2010263889A (ja) 2010-11-25
CY1107657T1 (el) 2013-04-18
EP1141286A4 (en) 2002-06-26
JP2003511007A (ja) 2003-03-25
JP5519087B2 (ja) 2014-06-11
BR9916209A (pt) 2001-12-26
NZ512942A (en) 2004-01-30
ES2277460T3 (es) 2007-07-01

Similar Documents

Publication Publication Date Title
MXPA01006006A (es) Cadena receptora de citocina.
MY150237A (en) Cripto blocking antibodies and uses thereof
MY151032A (en) Treatment of tnf? related disorders
DE69840699D1 (de) Heregulin varianten
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
ZA200604605B (en) Antibodies that bind interleukin-4 receptor
NO20011759D0 (no) Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi
NO985574L (no) FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
TW200631594A (en) Toll like receptor 3 antagonists, methods and uses
EP1034188A4 (en) METHOD FOR DESIGNING AGONISTS AND ANTAGONISTS OF THE IGF RECEPTOR
EP1566440A3 (en) Human Interleukin-11 Receptor
DE69738370D1 (de) Modulatoren des tnf-rezeptor-assoziierten faktors, deren herstellung und verwendungen
TNSN04015A1 (en) Combination therapy for the treatment of cancer
DE60128701D1 (en) Claudin polypeptide
NZ315514A (en) Tumour necrosis factor associated factor (traf) inhibitors including traf polypeptide, murine nucleotide sequence and associated assays
IL149416A0 (en) Human enzymes of the metalloprotease family
WO2002002630A3 (en) Hcn polypeptides and polynucleotides and their use in therapy
AU6308801A (en) Mu-1, member of the cytokine receptor family
EP1255110A3 (en) Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders
PE20399A1 (es) Muteina ob
WO2002057433A3 (de) Hipk-kinasen zur verwendung in der beeinflussung von zellteilung und zellproliferation
NO971553D0 (no) Cytoplasmisk tyrosinkinase
SG158098A1 (en) Toll like receptor 3 antagonists, methods and uses
WO2002000826A3 (fr) Nouveau polypeptide, proteine humaine de methylation d'adn, et polynucleotide codant ce polypeptide
DE69836971D1 (de) Methode und apparat zur vorhersage von funktionellen proteindomänen, methode zur verbesserung der proteinfunktion, sowie funktionell verbessertes protein

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: INVISTA TECHNOLOGIES S.A.R.L.

FG Grant or registration
MM Annulment or lapse due to non-payment of fees